---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-099422"
form_type: "8-K"
ticker: "IMA"
cik: "0001835579"
company_name: "ImageneBio, Inc."
filed_at: "2026-03-10T23:59:59+00:00"
generated_at: "2026-05-15T16:57:18.339362+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# ImageneBio reports Q4 2025 net loss $6.9M; cash $135.3M; Phase 2b ADAPTIVE on track for 2027

## Summary
- Cash, equivalents and marketable securities: $135.3M at Dec 31, 2025 vs $12.1M at Dec 31, 2024, after merger and $75M private placement.
- Net loss Q4 2025: $6.9M vs $4.8M Q4 2024, driven by post-merger operating costs and transaction expenses.
- Phase 2b ADAPTIVE trial (IMG-007 in atopic dermatitis) enrolling on schedule; blinded safety review found no pyrexia/chills/ulcers/malignancies.
- Appointed Dr. Ben Porter-Brown as CMO in Feb 2026; also added CEO, CSO, CTO, and an independent director during 2025.
- Submitted protocol amendment to expand dosing regimens, evaluate loading doses, and test patient-friendly intervals in ADAPTIVE.

## SEC filing metadata
- accession: 0001193125-26-099422
- form_type: 8-K
- ticker: IMA
- cik: 0001835579
- company_name: ImageneBio, Inc.
- filed_at: 2026-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/0001193125-26-099422-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/d130344d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-099422
- JSON: https://secwatch.observer/filing/0001193125-26-099422.json
- Plain text: https://secwatch.observer/filing/0001193125-26-099422.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.